Science
Publications and Posters
Belumosudil (KD025) and cGVHD
- 8/29/2020BELUMOSUDIL (KD025) For Patients with Chronic Graft Versus Host Disease (cGVHD): Long Term Follow Up of a Phase 2A Study (KD025 208). European Society for Blood and Bone Marrow Transplantation. 2020.
View - 8/29/2020Analysis of the ROCKstar Study: A Phase 2, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of BELUMOSUDIL (KD025) in Subjects With cGVHD. European Society for Blood and Bone Marrow Transplantation. 2020.
View - 5/27/2020Presentation and Management of cGVHD in Real-World Clinical Practice: A Medical Chart Audit. European Hematology Association. 2020.
View - 2/23/2020Interim Analysis of KD025-213: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) after at Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study). Transplantation and Cellular Therapy Meetings. 2020.
View - 2/19/2020KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) Long-term Follow-up of a Phase 2a Study (KD025-208). Transplantation and Cellular Therapy Meetings. 2020.
View - 12/9/2019Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation (HCT): A U.S. Claims Analysis. ASH Annual Meeting and Exposition. 2019.
View
Immuno-oncology: IL-15 Fusion Protein Platform
- 4/10/2021A Phase 1 Multiple Ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.. American Association for Cancer Research. 2021.
View - 2/5/2021Single-Dose Anti PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses. Molecular Cancer Therapeutics. 2021.
View - 11/11/2020A novel human anti-PD1/IL15 bi-functional protein with robust anti-tumor activity and low systemic toxicity. The Society for Immunotherapy of Cancer. 2020.
View - 6/24/2020Anti-PD-L1/IL15 fusion protein KD033 demonstrated efficient T cell redirected killing of PD-L1 expressing target cells and in vivo efficacy that correlated to its retention in tumors. American Association for Cancer Research. 2020.
View - 6/24/2020A novel anti-PD1-IL-15 immunocytokine potentiates anti-tumor T cell activity of PD-1 checkpoint blockade and IL-2/15R-beta-gamma agonism. American Association for Cancer Research. 2020.
View - 12/12/2019Anti-PDL1/IL-15 fusion protein increases efficacy-associated rare effector cells in cynomolgus monkey and mouse peripheral blood. European Society for Medical Oncology. 2019.
View - 11/1/2019Synergistic efficacy of anti-PD-L1/IL-15 fusion protein in combination with anti-CTLA-4 antibody in a murine orthotopic 4T1 breast carcinoma model. Society for Immunotherapy of Cancer. 2019.
View
ROCK Inhibition
- 1/14/2018Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. The Journal of Immunology. 2018.
Read More - 6/19/2016ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. Sci. Signal. 2016.
Read More - 6/16/2016
- 4/28/2016Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016.
Read More - 4/1/2015
- 11/25/2014Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. PNAS. 2014.
Read More - 1/1/2014